Digest Network Come funziona
Network
/
Società
Ag
Non verificato

Agenus Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

84 comunicati stampa

Guarda tutti i comunicati
09/10/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
08/10/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
03/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
02/10/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
10/09/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
31/08/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Participate in Upcoming September Investor Conferences
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
28/08/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
26/08/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
06/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
28/07/2026
Web e Social Network
Finanza
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0